

CLAIMS

What is claimed:

- 1 1. A method of treating one or more cells undergoing uncontrolled growth
2 comprising the step of:
3 contacting one or more cells with an antibody to RLIP76.
- 1 2. The method of claim 1, wherein one or cells are selected from the group
2 consisting of cancerous cells, NCI-H82, NCI-H182, NCI-1417, NCI-1618, NCI-H1395,
3 NCI-H2347, HCC44 (adenocarcinoma), and NCI-H2126 (large cell), and combinations
4 thereof.
- 1 3. The method of claim 1, wherein the antibody to RLIP76 inhibits the
2 transport activity of RLIP76.
- 1 4. The method of claim 1, wherein the antibody is added in combination with
2 a drug to prevent the drug from leaving the cell.
- 1 5. The method of claim 4, wherein the drug is used for chemotherapy.
- 1 6 The method of claim 1, wherein the antibody is selected from the group
2 consisting of a monoclonal antibody, a polyclonal antibody, RLIP76 IgG raised against
3 an effective portion of RLIP76.
- 1 7. The method of claim 4, wherein the drug is at least selected from the group
2 consisting of doxorubicin, actinomycin, actinomycin D, altretamine, asparaginase,
3 bleomycin, busulphan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin,
4 cyclophosphamide, cytarbine, dacarabazine, daunorubicin, , epirubicin, etoposide,
5 fludarbine, fluorouracil, gemcitabine, herceptin, hydroxyurea, idarubicin, ifosfamide,
6 irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin,
7 mitozantrone, oxaliplatin, procarbazine, rituxan, steroids, streptozocin, taxol, taxotere,
8 tamozolomide, thioguanine, thiotepa, tomudex, topotecan, treosulfan, uracil-tegufur,
9 vinblastine, vincristine, vindesine, vinorelbine, and effective combinations and analogs
10 thereof.

- 1 8. The method of claim 4, wherein addition of the drug to the antibody
2 enhances the cytotoxicity of the drug.
- 1 9. The method of claim 4, wherein antibody promotes apoptosis of the cell.
- 1 10. The method of claim 1, wherein the antibody is added in combination with
2 radiation therapy.
- 1 11. The method of claim 10, wherein the antibody in combination with
2 radiation therapy enhances effectiveness of the radiation therapy.
- 1 12. A pharmaceutical composition for the treatment of one or more cells
2 undergoing uncontrolled growth comprising:
3 an antibody to RLIP76, wherein the antibody comprises all or an effective
4 portion thereof that effectively reduces the transport activity of RLIP76; and
5 a pharmaceutically effective carrier.
- 1 13. The pharmaceutical composition of claim 11, wherein the antibody is
2 selected from the group consisting of a monoclonal antibody, a polyclonal antibody,
3 RLIP76 IgG raised against an effective portion of RLIP76.
- 1 14. The pharmaceutical composition of claim 11, wherein the pharmaceutical
2 composition is used in combination with a drug.
- 1 15. The pharmaceutical composition of claim 11, wherein addition of the drug
2 to the pharmaceutical composition enhances the cytotoxicity of the drug.
- 1 16. The pharmaceutical composition of claim 11, wherein the pharmaceutical
2 composition is used in combination with radiation therapy.
- 1 17. The pharmaceutical composition of claim 11, wherein radiation of the
2 pharmaceutical composition enhances the effect of radiation treatment.
- 1 18. The pharmaceutical composition of claim 11, wherein the pharmaceutical
2 composition promotes apoptosis of the cells.

19. A method of locating a cell undergoing uncontrolled growth comprising the step of:

contacting one or more cells with an antibody to RLIP76, wherein the antibody is connected to tracer molecule and the tracer molecule is capable of identifying the location
5 of the cell.

20. The method of claim 17, wherein the antibody is administered to mammal.